Pharma BD Deal Intelligence
A $460M bolt-on that Lonza quietly folded into what became the world's leading biologics CDMO. Nearly two decades later the Bioproducts and Walkersville, MD assets still operate as branded Lonza units with no writedown or divestiture on record.
A $460M bolt-on that quietly became part of the foundation for Lonza's multi-billion-dollar CDMO/biologics juggernaut
Full analysis, sources & comparables →Cambrex announced $460M cash sale of bio businesses; net proceeds ~$450M to repay debt and fund a $13.50–$14.50/share special dividend, refocusing on Human…
Deal closed February 2007 (announced Oct 2006); Lonza emerged as a top-tier global biologics CDMO with significantly expanded mammalian and microbial capacity.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Lonza acquired Cambrex's Bioproducts and Biopharma businesses for $460 million in cash, the largest acquisition in Lonza's history at the time, consolidating its position as a leading biopharmaceutical CDMO. Cambrex used the roughly $450 million net proceeds to repay debt and fund a special dividend while refocusing on its human-health small-molecule API business; the deal closed in February 2007.
A $460M bolt-on that quietly became part of the foundation for Lonza's multi-billion-dollar CDMO/biologics juggernaut
Assessment window: 15yr post-close.
$190M Acquired Bioproducts/Biopharma 2005 sales
This deal does not target a specific disease — it transferred Cambrex's contract biologics manufacturing and cell-biology bioproducts businesses to Lonza, expanding Lonza's biopharmaceutical CDMO footprint to support therapeutic proteins, vaccines, and other biologics across multiple disease areas.
The mid-2000s biologics CDMO market was consolidating around scale players capable of cGMP mammalian-cell manufacturing for monoclonal antibodies and recombinant proteins, with Lonza, Boehringer Ingelheim BioXcellence, Avecia (later acquired by Merck KGaA), DSM Biologics, and Catalent (then-Cardinal pre-spin) competing for capacity contracts. Cambrex's Bioproducts segment (cell culture media, sera, electrophoresis reagents, BioWhittaker franchise) and Biopharma segment (process development and cGMP biomanufacturing) generated $189.84M in 2005 sales, ~42% of total Cambrex revenue. The deal was Lonza's largest acquisition ever and consolidated its position as the world's leading biopharmaceutical CDMO by capacity, particularly strengthening cell-culture media, microbial fermentation, and mammalian cGMP manufacturing — capabilities critical to the rising mAb wave (Humira, Avastin, Herceptin, Rituxan generation). For Cambrex, it was a strategic exit to refocus on small-molecule API and pay down debt plus a $13.50–$14.50/share special dividend. Source: https://www.genengnews.com/news/lonza-makes-its-largest-acquisition-cambrex-bio-businesses-for-460m/
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses (this deal) | 2006 | $460M | 83 |
| Lonza Group AG / Capsugel S.A. | 2016 | $5.5B | 44 |
| Lonza Group AG / Capsugel S.A. (KKR portfolio) | 2016 | $5.5B | 39 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
← Browse all deals · How we score deals
More: 2006 deals · Lonza Group AG deals